AbstractBenign prostatic hyperplasia (BPH) may alter prostatic fluid biochemical composition causing reduced fertility. Osaterone acetate (OA) is an androgen receptor antagonist marketed for treatment of canine BPH. Little information exists on effects of OA administration on biochemical composition of canine prostatic fluid and its role on fertility. The aim of this research was to study biochemical composition of prostatic fluid and its role on semen quality in dogs with BPH undergoing treatment with OA. Eight intact, 5–11‐year‐old dogs with benign prostatic hyperplasia were treated orally with OA at a dose of 0.25–0.5 mg/kg once daily for seven days. Prostatic volume, semen evaluation and a biochemical analysis of prostatic fluid were performed on the day before treatment (D0), D60, D120, D180 and D240. A significant reduction (57% and 61%) of prostatic volume was observed at D60 and D120, respectively, and a significant reduction (20%) of normal spermatozoa was observed at D60 coincident with a significant increase of sperm tail defects, which disappeared during the course of the treatment. Prostatic fluid composition did not vary during the OA treatment except for zinc (Zn2+) with a significant increase at D120 and D180 correlated with the return to normal sperm values. In conclusion, canine Zn2+ prostatic fluid concentrations decrease during development of BPH and return to normal during treatment with OA. Zn2+ is an important electrolyte for semen quality, suggesting that oral Zn2+ supplementation might be considered a treatment to improve semen quality.

05 Jun 2021·Acta Veterinaria Hungarica

Acute colonic impaction and faecaloma due to canine benign prostatic hyperplasia – Case report

Author: Ferré-Dolcet, Lluis ; Sussan, Beatrice

AbstractThe present case report describes the clinical signs and case resolution of an intact 9-year-old male crossbreed dog with spontaneous constipation. The dog presented with abdominal pain, lack of appetite, tenesmus and without signs of defecation in the last 4 days. No important alterations were observed in the complete blood count and biochemistry. A substantial obstruction caused by a faecaloma and a prostate with increased size was observed on X-rays. Benign prostatic hyperplasia (BPH) was confirmed by ultrasonography (size: 48.29 cm3) and by testing the serum canine prostate-specific arginine esterase concentration (105.97 ng/mL). Colon impaction was resolved with rectal enemas within two days. BPH was treated with osaterone acetate. Ultrasonographic checks were performed after 60 and 180 days from the demission and a concrete constant reduction of prostatic volume and of the clinical signs was established. Faecaloma is an uncommon finding in male dogs, and it occurs especially as a consequence of BPH. Colon impaction in patients with BPH is usually subclinical, but it is important to underline how, in severe cases, perforation of the colon and faecal peritonitis can occur, leading to fatal conditions for the animal. In conclusion, prostatic enlargement should always be considered in male dogs suffering from colonic impaction.

01 Jun 2014·Reproduction in Domestic Animals

Pharmacological Treatment for Common Prostatic Conditions in Dogs – Benign Prostatic Hyperplasia and Prostatitis: an Update

Review

Author: Ochota, M ; Levy, X ; Pasikowska, J ; Niżański, W

ContentsThe two most frequent prostatic diseases in dogs are benign prostatic hyperplasia (BPH) and prostatitis. Prostatitis requires prolonged antibiotic treatment. In acute prostatitis, the blood–prostate barrier is broken, thus facilitating the penetration of antibiotics, whereas in chronic prostatitis, the barrier prevents the penetration of many drugs into the gland. The selection of antibiotic agents is based on the sensitivity test and the drug's ability to penetrate into the gland. Many protocols for the treatment ofBPHare available. In non‐breeding dogs, surgical and optionally pharmacological castration by means of GnRHagonists may be performed. In breeding dogs, drugs retaining fertility are used. Recently, androgen receptor antagonistic treatment with osaterone acetate has been applied. Other drugs used forBPHtreatment include progestagens, oestrogens, antioestrogens and 5α‐reductase inhibitors. Some of these compounds may provoke severe side effects. The efficiency of GnRHantagonists used for the treatment of prostatic diseases, such as neoplasia andBPH, in humans has been recently investigated in dogs. This androgen deprivation therapy (ADT) is devoid of an initial exacerbation of androgen‐dependent symptoms, which is typical for GnRHagonistic treatment. In many cases,BPHand prostatitis must be treated simultaneously as these conditions may develop in combination.

100 Deals associated with Osaterone acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D11105	-	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Osteoporosis, Postmenopausal	Phase 2	-	ASKA Pharmaceutical Co., Ltd.	-
Prostatic Cancer	Phase 2	-	ASKA Pharmaceutical Co., Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis